(Q37032556)

17 August 2017

1 reference

title

Antiretroviral therapy : optimal sequencing of therapy to avoid resistance (English)

1 reference

17 August 2017

main subject

anti-retroviral agent

0 references

2

Mark A Wainberg

1 reference

17 August 2017

1

Jorge L Martinez-Cajas

1 reference

17 August 2017

publication date

1 January 2008

1 reference

17 August 2017

1 reference

17 August 2017

volume

68

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

43-72

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200868010-00004

17 August 2017

exact match

0 references

cites work

Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

1 reference

12 December 2020

Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture

1 reference

12 December 2020

Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples

1 reference

12 December 2020

Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance

1 reference

12 December 2020

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

12 December 2020

Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

1 reference

12 December 2020

Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ L in HIV Type 1--Infected Individuals Receiving Potent Antiretroviral Therapy

1 reference

12 December 2020

Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors

1 reference

12 December 2020

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

1 reference

12 December 2020

A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors

1 reference

12 December 2020

In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.

1 reference

12 December 2020

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis

1 reference

12 December 2020

HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC).

1 reference

12 December 2020

Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients

1 reference

12 December 2020

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease

1 reference

12 December 2020

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates

1 reference

12 December 2020

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

1 reference

12 December 2020

HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%.

1 reference

12 December 2020

Entire genome of a strain of human immunodeficiency virus type 1 with a deletion of nef that was recovered 20 years after primary infection: large pool of proviruses with deletions of env.

1 reference

12 December 2020

Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection.

1 reference

12 December 2020

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

1 reference

12 December 2020

Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).

1 reference

12 December 2020

Nef alleles from human immunodeficiency virus type 1-infected long-term-nonprogressor hemophiliacs with or without late disease progression are defective in enhancing virus replication and CD4 down-regulation

1 reference

12 December 2020

Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine

1 reference

12 December 2020

Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters

1 reference

12 December 2020

Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART

1 reference

12 December 2020

Linking HIV and Antiretroviral Drug Resistance Surveillance in Peru

1 reference

12 December 2020

Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy

1 reference

12 December 2020

An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugs

1 reference

12 December 2020

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects

1 reference

12 December 2020

Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure

1 reference

12 December 2020

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine

1 reference

12 December 2020

Antiretroviral therapy. Sequencing antiretrovirals.

1 reference

12 December 2020

Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.

1 reference

12 December 2020

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

1 reference

12 December 2020

The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations

1 reference

12 December 2020

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

1 reference

12 December 2020

Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission

1 reference

12 December 2020

A randomized controlled psycho-education intervention trial: Improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART.

1 reference

12 December 2020

A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen

1 reference

12 December 2020

Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors

1 reference

12 December 2020

Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients.

1 reference

12 December 2020

The impact of the M184V substitution on drug resistance and viral fitness

1 reference

12 December 2020

A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.

1 reference

12 December 2020

Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens

1 reference

12 December 2020

Update of the drug resistance mutations in HIV-1: Fall 2006.

1 reference

12 December 2020

Decreased recovery of CD4 lymphocytes in older HIV-infected patients beginning highly active antiretroviral therapy

1 reference

12 December 2020

Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region

1 reference

12 December 2020

Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen

1 reference

12 December 2020

Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing

1 reference

12 December 2020

Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.

1 reference

12 December 2020

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

12 December 2020

Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues

1 reference

12 December 2020

Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations

1 reference

12 December 2020

Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts

1 reference

12 December 2020

Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe

1 reference

12 December 2020

Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial

1 reference

12 December 2020

Pharmacokinetic enhancement of protease inhibitor therapy

1 reference

12 December 2020

HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia.

1 reference

12 December 2020

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

1 reference

12 December 2020

Update on primary HIV-1 resistance in Argentina: emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase inhibitors in drug-naive patients.

1 reference

12 December 2020

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients

1 reference

12 December 2020

Trends in drug resistance mutations in antiretroviral-naïve intravenous drug users of Rio de Janeiro

1 reference

12 December 2020

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon.

1 reference

12 December 2020

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy

1 reference

12 December 2020

Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure

1 reference

12 December 2020

A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women

1 reference

12 December 2020

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

12 December 2020

Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones

1 reference

12 December 2020

Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens

1 reference

12 December 2020

Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy

1 reference

12 December 2020

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)]

1 reference

12 December 2020

Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus

1 reference

12 December 2020

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial

1 reference

12 December 2020

Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil

1 reference

12 December 2020

Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen

1 reference

12 December 2020

Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads

1 reference

12 December 2020

Resistance costs and future drug options of antiretroviral therapies: analysis of the role of NRTIs, NNRTIs, and PIs in a large clinical cohort

1 reference

12 December 2020

Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

1 reference

12 December 2020

Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

1 reference

12 December 2020

Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.

1 reference

12 December 2020

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

1 reference

12 December 2020

Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years

1 reference

12 December 2020

Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.

1 reference

12 December 2020

Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine

1 reference

12 December 2020

Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine

1 reference

12 December 2020

Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs

1 reference

12 December 2020

Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precur

1 reference

12 December 2020

Resistance to HIV drugs in UK may be lower in some areas

1 reference

12 December 2020

Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues

1 reference

12 December 2020

Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial

1 reference

12 December 2020

HIV-1 pol gene polymorphism and antiretroviral resistance mutations in drug-naive pregnant women in Yaoundé, Cameroon

1 reference

12 December 2020

Trends in antiretroviral drug resistance and clade distributions among HIV-1--infected blood donors in Sao Paulo, Brazil

1 reference

12 December 2020

Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy

1 reference

12 December 2020

Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy

1 reference

12 December 2020

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure

1 reference

12 December 2020

A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV.

1 reference

12 December 2020

N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure

1 reference

12 December 2020

Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group

1 reference

12 December 2020

Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview

1 reference

12 December 2020

The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response

1 reference

12 December 2020

Replication-defective HIV isolated from seronegative individuals at high risk for HIV infection

1 reference

12 December 2020

Response to antiretroviral therapy after a single, peripartum dose of nevirapine

1 reference

12 December 2020

A rational approach to the selection and sequencing of nucleoside/nucleotide analogues: a new paradigm

1 reference

12 December 2020

Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89

1 reference

12 December 2020

A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation

1 reference

12 December 2020

A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).

1 reference

12 December 2020

Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group

1 reference

12 December 2020

Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.

1 reference

12 December 2020

Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir

1 reference

12 December 2020

Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy

1 reference

12 December 2020

Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience

1 reference

12 December 2020

Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study

1 reference

12 December 2020

Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients

1 reference

12 December 2020

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

1 reference

12 December 2020

Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase

1 reference

12 December 2020

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study

1 reference

12 December 2020

The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors

1 reference

12 December 2020

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

1 reference

12 December 2020

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.

1 reference

12 December 2020

Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients

1 reference

12 December 2020

Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population

1 reference

12 December 2020

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial

1 reference

12 December 2020

Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe

1 reference

12 December 2020

HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy

1 reference

12 December 2020

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

1 reference

12 December 2020

The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001

1 reference

12 December 2020

Transmitted drug-resistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy.

1 reference

12 December 2020

Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort

1 reference

12 December 2020

Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients.

1 reference

12 December 2020

Natural history of HIV infection in the era of combination antiretroviral therapy

1 reference

12 December 2020

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

1 reference

12 December 2020

An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine

1 reference

12 December 2020

Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution

1 reference

12 December 2020

In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine

1 reference

12 December 2020

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

12 December 2020

Might the M184V substitution in HIV-1 RT confer clinical benefit?

1 reference

12 December 2020

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

1 reference

12 December 2020

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine

1 reference

12 December 2020

Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads

1 reference

12 December 2020

Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy

1 reference

12 December 2020

Predominance of defective proviral sequences in an HIV + long-term non-progressor

1 reference

12 December 2020

Thermodynamic Basis of Resistance to HIV-1 Protease Inhibition: Calorimetric Analysis of the V82F/I84V Active Site Resistant Mutant†

1 reference

12 December 2020

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

1 reference

12 December 2020

Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir

1 reference

12 December 2020

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

1 reference

12 December 2020

Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors

1 reference

12 December 2020

Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen

1 reference

12 December 2020

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients

1 reference

12 December 2020

Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy

1 reference

12 December 2020

Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples

1 reference

12 December 2020

Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients

1 reference

12 December 2020

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CP

1 reference

12 December 2020

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

12 December 2020

Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons

1 reference

12 December 2020

Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus

1 reference

12 December 2020

Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies

1 reference

12 December 2020

Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load

1 reference

12 December 2020

A prospective study of predictors of adherence to combination antiretroviral medication

1 reference

12 December 2020

Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient

1 reference

12 December 2020

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

1 reference

12 December 2020

The M184V mutation: what it does, how to prevent it, and what to do with it when it's there.

1 reference

12 December 2020

Paradoxes of adherence and drug resistance to HIV antiretroviral therapy

1 reference

12 December 2020

Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults

1 reference

12 December 2020

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

12 December 2020

Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.

1 reference

12 December 2020

Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy

1 reference

12 December 2020

Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate

1 reference

12 December 2020

Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART

1 reference

12 December 2020

Fosamprenavir clinical study meta-analysis in ART-naïve subjects: rare occurrence of virologic failure and selection of protease-associated mutations.

1 reference

12 December 2020

Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors

1 reference

12 December 2020

A Simple Screening Approach to Reduce B*5701-Associated Abacavir Hypersensitivity on the Basis of Sequence Variation in HIV Reverse Transcriptase

1 reference

12 December 2020

Detection of Mutations Associated with Zidovudine Resistance in Human Immunodeficiency Virus by Use of the Polymerase Chain Reaction

1 reference

12 December 2020

Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study

1 reference

12 December 2020

Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing.

1 reference

12 December 2020

10.2165/00003495-200868010-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

17 August 2017

1045189866

0 references

1 reference